Adult stem cell therapy is enjoying widespread success around the world, but if the FDA gets its way, it may soon be banned here in the U.S....
There have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions. It involves using the patients own stem cells, so no patent-able drugs are involved.
They are targeting the most influential stem cell scientist in the U.S., Dr. Kristin Comella in Florida.
Differentiating the Types of Stem Cell Therapy
They could be considered seeds for growing body tissues. They are mostly able to function for cellular repair and growth no matter what organ is in need of repair or healing from chronic inflammation.
There is a considerable controversy surrounding stem cell therapy research, a branch of regenerative medicine. Much of the controversy has to do with not differentiating between adult stem cell therapy and embryonic stem cell therapy.
Read: Scientists Discover That Fasting Triggers Stem Cell Regeneration & Fights Cancer
Embryonic stem cell therapy is the controversial one. It cultures or creates stem cells from terminated or aborted fetuses.
Currently, the FDA is harassing stem cell clinics that do not derive their stem cell solutions from aborted fetus tissue. They extract the stem cells from the patients own adipose tissue and inject them into areas where that same patient needs repair. Its an autologous process called adult stem cell therapy.
U.S. Stem Cell based out of South Florida is one of the clinics being targeted by the FDA, and the clinics Chief Scientist is Dr. Kristin Comella, PhD.
Many other nations have been using adult stem cell therapy successfully over the past 15 years, leaving the USA dead last in this field. The FDA is trying to make sure it stays that way and allows costly pharmaceutical versions to prevail.
Dr. Kristin Comella and her clinic have been under attack from the FDA.
This short 3-minute video was produced interviewing Dr. Comella and some of her patients.
Examining and Comparing the Different Types of Stem Cell Therapy
Human embryonic stem cell (hESC) therapy has received most of the medias attention and government support. But it is the most controversial because it involves extracting tissues from terminated human embryos, aka aborted fetuses.
In addition to moral and ethical issues, human embryonic stem cell (hESC) solutions create cells so rapidly where theyre injected they lead to cancerous tumors. To avoid that, researchers have to use immuno-suppressant drugs to curb the embryonic stem cells tendency toward cancer.
Using pharmaceutical drugs to curb hESC cancer side effect issues leads to other unexplored and unexpected side effects from those patented stem cell solutions.
But the profit motive for embryonic stem cell therapies was strong and a lot of government funds had been put into its research. Pharmaceutical companies were motivated because they could patent stem cells created from embryonic tissues.
Bone marrow stem cell therapy was among the first to depart from flawed hESC (human embryonic stem cell) therapies developed over the past two decades. Bone marrow stem cell therapy was the segue into the adult stem cell therapy movement.
Bone marrow extractions are painful, requiring general anesthesia. Its relatively difficult and expensive compared to adipose (fat) tissue stem cell harvesting.
Bone marrows high white blood cell count also encourages inflammation, making it counter-productive for patients already suffering from chronic inflammation or autoimmune disorders.
Most importantly, adipose (fat) tissue yields up to 500 times more mesenchymal stem cells than bone marrow sources, according to Dr. Comella. These are potent stem cells that can differentiate into a wide variety of other cell types. Furthermore, the adipose white blood cell count is lower than bone marrow matter.
Overactive, confused immune responses attack organs continually and create chronic inflammation and autoimmune diseases. The lower white blood cell count automatically lowers the risk of further inflammation among patients already suffering from chronic inflammation and autoimmune diseases.
The outpatient treatment involves creating a very small and shallow incision that wont require stitches on an area of skin covering adipose tissue (fat). From there, liposuction can withdraw a portion of the fat. This part of the procedure requires only a local anesthetic.
Then what is extracted is spun at high speed in a special centrifuge to isolate the stem cells which are then purified for IV drip delivery or injection into the same patient from whom it was extracted. Total costs range from five to ten thousand dollars or more in some cases.
Dr. Comella and her colleagues mission is to get adult stem cell therapy available for everyone. Private and government health insurance providers cover medical treatments that are much more expensive.
Why not cover one that would save money with its lower expense and fewer side effects?
Over the years, there have been nearly 12,000 adult stem cell therapies performed in the United States with an over 90 percent success healing rate for mostly joint and spinal conditions as well as heart and lung issues.
But the three known adverse side effect cases continually get all the media attention.
The Panama College of Cell Science, which helped launch Kristin Comellas research and development, had this to say about her:
"Perhaps the most influential clinician on the subject of adult stem cell therapy, Dr. Comella has been able to quietly develop patient treatment protocols and treat patients via collaborating physicians and health care providers using legal patient-specific FDA guidelines, including studies permitted by Institutional Review Boards, patient-specific stem cell clinical trials, and direct treatments using the patients own stem cells that are harvested and re-injected for therapeutic purposes.
"Through Dr. Comellas leadership, she and her team have trained and certified more than 700 physicians worldwide in adult stem cell therapy." (Source)
The interview below allows the energetic Dr. Kristin Comella to give a thorough and upbeat description of adult stem cell therapy.
Big Pharma Is Using the FDA to Eliminate Unregulated Adult Stem Cell Competition
Since the late 1990s, adult stem cells used therapeutically were not under the control of the FDA and the adult stem cell movement took off.
There were complaints from some MDs that the adult stem cell practice should be regulated by the FDA. The Panama College of Cell Science responded to those outcries with this statement:
"The motive in opposing adult stem cell therapy is money. The big institutions want to keep federal funding of embryonic stem cell research at a high level with the promise that cures are just around the corner despite the fact that embryonic stem cells will never be useful in any way for patient treatment because they immediately cause tumors when transplanted." (Source)
Adult stem cell therapy is an autologous treatment method. The stem cells are not lab-created. They are only isolated and purified after extracting them from the patient being treated. Injecting them back into that patient powers up the bodys own healing mechanism to overcome chronic ailments.
The FDA didnt and shouldnt have anything to do with regulating stem cells from ones own body. That situation has recently been arbitrarily and suddenly changed.
Around 2014, the FDA started tweaking their guidance rules for stem cell therapy with the purpose of getting new rules made into laws through Congress that could be interpreted according to FDA whims and enforced arbitrarily. Their agenda is to consider adult stem cells as FDA-regulated drugs.
During our phone conversation, Dr. Comella explained how the FDA ignored testimonies from adult stem cell practitioners during their 2015 public hearings regarding new guideline proposals. Then they arranged to create new rules behind closed door meetings that included pharmaceutical industry allies and insiders.
The result was that by 2017, the FDAs hands-off policy with adult stem cell therapy came to a sudden halt after years of highly successful stem cell practice.
By 2018, the FDA got nastier with the the most influential clinician on the subject of adult stem cell therapy as its target. The FDA started doing inspections of Dr. Comellas South Florida clinic that are designed for labs that manufacture drugs.
The standards for hospitals and clinics are not as strict as drug manufacturers. Those inspections were inappropriate for a clinic. But those inspections made it easier to create damaging reports.
When the inspectors came by, they demanded to go into rooms while treatments were taking place with semi-nude or nude patients, which Dr. Comella prohibited. The inspectors also demanded to view patient medical records. She allowed that after redacting their names on the copies she gave them.
For her actions to protect patients privacy, inspectors allegedly cited Dr. Comella for resisting and obstructing FDA inspections.
Soon after the inspections, the FDA served Dr. Comella with a lawsuit for practicing medicine with unapproved drugs. The drugs were only those stem cell solutions drawn from patients to be used on them.
The FDA has allegedly offered to drop the lawsuit if Dr. Comella signed an agreement to stop doing adult stem cell therapy and no longer promote it.
She refused. She said she has witnessed people leave their wheelchairs for good from this therapy. The trial is set for a Federal Court hearing beginning June 2019, in Miami, Florida.
If Dr. Comella loses this court case, adult stem cell therapy in the USA may be forced out of the country and only be available to those who can afford medical tourism.
Here is the original post:
Adult Stem Cell Therapy Is A Resounding Healing Success, So ...
- Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press - December 6th, 2019
- Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description - December 6th, 2019
- Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast... - December 6th, 2019
- Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal - December 5th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates - December 5th, 2019
- Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24 - December 5th, 2019
- Stem Cell Market 2019 | What Will Be the Market Size and the Growth Rate Analysis by 2026? - Hitz Dairies - December 3rd, 2019
- Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash - December 3rd, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace - November 28th, 2019
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 28th, 2019
- Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor - November 28th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info - November 28th, 2019
- Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger - November 28th, 2019
- Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times - November 28th, 2019
- Types of Adult Stem Cells - Stem Cell Institute - November 26th, 2019
- Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute - November 26th, 2019
- Hatching disease in a dish: The new frontier in drug testing - Maclean's - November 26th, 2019
- Bedfordshire Police officer reunited with woman whose life he saved through stem cell donation - Bedford Today - November 26th, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - GlobeNewswire - November 26th, 2019
- Bedfordshire Police officer reunited with stem cell recipient - Cranfield and Marston Vale Chronicle - November 26th, 2019
- Keeping cells alive | Interviews - The Naked Scientists - November 26th, 2019
- Dana-Farber joins with leading Boston teaching hospitals and universities - Mirage News - November 26th, 2019
- Applying AI and CRISPR to stem cells to improve regenerative medicine - FierceBiotech - November 20th, 2019
- Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK - November 20th, 2019
- 1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective - Sickle Cell Anemia News - November 20th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - BioSpace - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star - November 20th, 2019
- Maltese abroad: the best-selling author with roots in Gozo - Times of Malta - November 20th, 2019
- Early Results Are Positive for Experimental CRISPR Therapies - The Scientist - November 19th, 2019
- CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub - November 19th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire - November 19th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 16th, 2019
- Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst - November 16th, 2019
- How 3D Printing Is Turning Each And Every Industry On Its Head - SafeHaven.com - November 16th, 2019
- BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive - November 16th, 2019
- Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 - Galus Australis - November 16th, 2019
- Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell... - November 15th, 2019
- Bone marrow transplant: What it is, uses, risks, and recovery - Medical News Today - November 15th, 2019
- The Demand of Mesenchymal Stem Cells Market Research Report 2019 Future Growth, Demand, Application, Trends, Vendor Landscape, Industry Insight,... - November 15th, 2019
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society - Yahoo Finance - November 14th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 14th, 2019
- BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - Yahoo Finance - November 14th, 2019
- INDIA Indian doctor: Medical innovation should not try to replace the Creator - AsiaNews - November 14th, 2019
- iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting - Send2Press Newswire - November 14th, 2019
- Contrasting BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 14th, 2019
- Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell... - November 12th, 2019
- Army veteran to save woman with blood cancer through stem cell donation - Stoke-on-Trent Live - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Autolus Therapeutics Plc (AUTL) Q3 2019 Earnings Call Transcript - The Motley Fool - November 9th, 2019
- Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate... - October 29th, 2019
- Huntington's Marked by Inflammation and Changes in Brain's Striatum Before Symptoms, Study Finds - Huntington's Disease News - October 29th, 2019
- In 2030, Our Protein Will Come From a Laband We'll All Be Better Off For It - Singularity Hub - October 28th, 2019
- NASA plans to cut cost of space exploration by commercializing low-earth orbit - Digital Trends - October 27th, 2019
- BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - BioSpace - October 27th, 2019
- Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs - IFLScience - October 21st, 2019
- Healthcare Terms Are Out of Touch, Says Mom Advocate - Medscape - October 21st, 2019
- A stop-motion movie of the whole brain, starring new neurons - Spectrum - October 21st, 2019
- Humans evolved to think faster by slowing down brain development - New Scientist News - October 21st, 2019
- Stem Cell Banking Market was valued at $1986 million in 2016 - Markets Gazette - October 19th, 2019
- Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner - October 17th, 2019
- The Other Side of Stem Cell Research - The Tablet Catholic Newspaper - October 17th, 2019
- Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 17th, 2019
- SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly - October 17th, 2019
- Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine - October 17th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly - October 17th, 2019
- Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T... - October 7th, 2019
- New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist - October 7th, 2019
- Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte - October 7th, 2019
- Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine - American Council on Science and Health - October 6th, 2019
- We're making tiny brains in the lab should we be worried for them? - CBC.ca - October 6th, 2019
- Female Scientist To Lead Advanced Cancer Research Project In Space - SheThePeople - October 6th, 2019
- Cancer cells to be tested in zero gravity on Chinese Space Station - E&T Magazine - October 4th, 2019
- Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic... - October 4th, 2019
- Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research - October 4th, 2019
- Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple... - September 27th, 2019
- The unexpected functional diversity of reactive astrocytes - Baylor College of Medicine News - September 27th, 2019
- Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News - September 27th, 2019
- Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 - Herald Space - September 27th, 2019